Dyne Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
John Cox
Chief executive officer
US$20.8m
Total compensation
| CEO salary percentage | 2.58% |
| CEO tenure | 2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.3yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Dyne Therapeutics: Why The $350M Public Offering Was Critical
Dec 10Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?
Jun 17
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Mar 13We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Feb 28Dyne Therapeutics: Moving Forward On 2 Key Fronts
Jan 24We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Nov 12Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Nov 11Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street
Sep 04Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth
Aug 14Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials
May 21We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
May 04Dyne: H2 2024 Muscle Disease Data Could Boost Value
Mar 05We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Dec 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
Aug 09We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Mar 26We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Dec 10Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?
Aug 26Dyne wins regulatory nod to start trial for myotonic dystrophy candidate
Jul 12Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251
Jul 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$446m |
| Sep 30 2025 | n/a | n/a | -US$424m |
| Jun 30 2025 | n/a | n/a | -US$413m |
| Mar 31 2025 | n/a | n/a | -US$367m |
| Dec 31 2024 | US$21m | US$537k | -US$317m |
Compensation vs Market: John's total compensation ($USD20.84M) is above average for companies of similar size in the US market ($USD6.96M).
Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.
CEO
John Cox (62 yo)
Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 2024. He also serves as Atlas Advisor at Atlas Venture Advisors, Inc. (formerly known...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2yrs | US$20.84m | 0.097% $ 2.8m | |
| Chief Innovation Officer | less than a year | US$3.84m | 0.026% $ 755.2k | |
| Chief Commercial Officer | 1.5yrs | US$8.54m | 0.014% $ 396.4k | |
| Chief Medical Officer | 1.5yrs | US$8.09m | 0.0096% $ 279.1k | |
| CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer | 1yr | no data | no data | |
| Senior VP and Head of Portfolio Strategy & Operations | 1.2yrs | no data | no data | |
| Chief Technical Officer | less than a year | no data | no data | |
| Chief Digital & Information Officer | less than a year | no data | no data | |
| Senior VP & Head of Legal | 3.1yrs | no data | no data | |
| Chief Human Resource Officer | 1.5yrs | no data | no data | |
| Chief Regulatory Affairs Officer | 5.8yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
Experienced Management: DYN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2yrs | US$20.84m | 0.097% $ 2.8m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.3yrs | US$546.85k | 0% $ 0 | |
| Independent Director | 6yrs | US$560.85k | 0.032% $ 941.5k | |
| Independent Chairman | 8.3yrs | US$579.85k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$559.35k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.7yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | US$554.35k | 0.054% $ 1.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data |
Experienced Board: DYN's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/23 08:57 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dyne Therapeutics, Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| William Pickering | Bernstein |
| Keay Nakae | Chardan Capital Markets, LLC |